HR-4709-119
Forwarded by Subcommittee to Full Committee by Voice Vote.
Sponsored by Kelly Morrison (D-MN)
What it does
This bill would reauthorize through FY2030 several federal programs related to newborn screening — the process of testing newborns for serious, often treatable conditions shortly after birth. It would make the Hunter Kelly Research Program at the National Institutes of Health mandatory (rather than discretionary), reauthorize national newborn disease surveillance activities at the CDC, and provide explicit statutory authority for existing regulations that allow federally funded research on leftover newborn blood samples (called residual blood spots) to proceed without the full human subjects research protections that would otherwise apply.
Who benefits
Newborns and their families, who would continue to benefit from early detection of serious conditions. Researchers at NIH and universities who study rare childhood diseases and would gain clearer legal authority to use residual blood samples. Public health officials at the CDC who conduct disease surveillance. Rare disease advocacy organizations that rely on federal research funding. Pharmaceutical and biotech companies developing treatments for conditions identified through newborn screening. States and hospitals that administer screening programs and benefit from federal coordination and funding.
Who is hurt
Parents and privacy advocates who object to the use of their newborns' blood samples for research without explicit informed consent — the statutory exemption from human subjects research rules (the "Common Rule") removes a layer of parental notification and consent. Civil liberties organizations concerned about the creation and use of biological databases. Researchers or institutions that currently operate under the existing regulatory framework may face compliance adjustments. Taxpayers who fund the mandatory NIH program, which would no longer be subject to annual discretionary appropriations decisions.
Supporters argue
Supporters argue that newborn screening is one of the most cost-effective public health interventions in American medicine, identifying dozens of treatable conditions — including PKU, sickle cell disease, and congenital hypothyroidism — before symptoms appear, preventing disability and death. They contend that making the Hunter Kelly Research Program mandatory ensures stable, uninterrupted funding for rare disease research that has historically been vulnerable to annual budget cuts. They further argue that the blood spot research exemption codifies a longstanding, carefully designed regulatory practice that enables critical population-level research while posing minimal privacy risk because samples are non-identified.
Opponents argue
Opponents argue that providing statutory authority to exempt residual newborn blood spot research from the Common Rule bypasses meaningful parental consent, treating infants' biological material as a public resource without family input. They contend that "non-identified" does not mean truly anonymous — advances in genomic re-identification techniques mean that de-identified samples can increasingly be linked back to individuals, raising serious privacy concerns. They further argue that making the Hunter Kelly Program mandatory removes congressional flexibility to redirect funding based on shifting research priorities, locking in spending without the accountability of annual appropriations review.